Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 1,974 $ 2,406
General and administrative 1,562 1,213
Operating loss (3,536) (3,619)
Other income:    
Other income, net 35 4
Total other income, net 35 4
Loss before income tax expense (3,501) (3,615)
Income tax expense (7) (7)
Net loss (3,508) (3,622)
Other comprehensive loss    
Unrealized loss on marketable securities (56) (2)
Net loss and comprehensive loss $ (3,564) $ (3,624)
Basic and diluted net loss per share (in dollars per share) $ (0.13) $ (0.19)
Weighted average shares outstanding – basic and diluted (in shares) 26,443,067 18,766,656